Evaluation of an Enhanced Tuberculosis Infection Control Intervention in Healthcare Facilities in Vietnam and Thailand (EnTIC)

February 1, 2021 updated by: Centers for Disease Control and Prevention

Study Design: Stratified, matched, cluster-randomized, controlled trial

Unit of Randomization: Healthcare facility

Study Duration: 3 years; prevalence of latent Tuberculosis infection (LTBI) in healthcare workers (HCWs) will be at measured at baseline, and LTBI incidence will be measured among susceptible HCWs at 12 and 24 months. Secondary outcomes will be measures at 0 (pre-intervention) 6, 12, 18, and 24 months. In year three, results will be analyzed and disseminated.

Study Components: Assessment of institutional safety culture; observations/audits of Tuberculosis (TB) patient flow (wait times) and HCW TB infection control (IC) practices; documentation of time intervals for processing sputum smears and initiation of TB treatment; facility assessments; random allocation and implementation of enhanced Tuberculosis infection control (TB IC) package; testing of HCWs to determine LTBI at 0, 12, 24 months; cost evaluation of intervention.

Sample Size: For the cluster randomized design, we estimate that 11 clusters per group will allow for 77 percent (%) power to identify a 30% reduction in LTBI incidence in the intervention vs. control clusters. This assumes LTBI incidence 5% per year in the control group, design effect for clustering of 2.0, and cluster size of 300 (average 600 HCW per cluster with 50% LTBI prevalence at baseline).

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

TB remains a cause of substantial morbidity and mortality, affecting an estimated 13.7 million persons and resulting in 1.8 million deaths worldwide. TB transmission has been well-documented in a wide variety of healthcare settings. Moreover, the global expansion of HIV care programs may inadvertently increase TB transmission in healthcare settings by congregating highly susceptible individuals with those likely to have TB disease. The urgency of reducing TB transmission in healthcare facilities has been intensified by the emergence of drug-resistant TB strains, including extensively resistant TB strains, and the high mortality of these strains in people living with human immunodeficiency virus (HIV).

Healthcare workers are at higher risk of both TB infection and disease compared to the general population, with estimates that 63-94% of TB infection and up to 89% of TB disease in this population is due to occupational exposure.

The World Health Organization (WHO) has identified institutional TB IC as one of the core "3 I's" interventions required to reduce the burden of TB among people living with HIV. Although TB IC guidelines exist and a "package" of interventions has been shown to successfully interrupt TB outbreaks in U.S. hospitals, there is limited information on feasibility, impact or cost of TB IC programs in middle- and low-income countries where TB burdens are high and nosocomial TB transmission has been well-documented.

Currently recommended TB IC strategies are complex and multi-faceted and include: administrative controls (e.g., early identification, treatment, and isolation or cohorting of infectious TB patients); effective engineering/environmental controls (such as, general ventilation or ultraviolet germicidal irradiation); and appropriate use of respiratory protection (N-95 particulate respirators) to protect HCWs. Implementation of many of these recommended measures require administrative/managerial support and sustained behavior change of frontline staff; some require substantial healthcare expenditures. There is an urgent need for simple, evidence-based and cost-effective strategies to help guide implementation of TB IC programs and reduce institutional TB transmission in resource-limited settings where TB and HIV are endemic. A recent call to address gaps in the TB IC evidence base identified key priorities including operational research to investigate the efficacy and cost-effectiveness of TB IC measures, and behavioral research to develop effective strategies to inform, motivate and provide skills to HCWs to implement and sustain effective airborne IC procedures and practices. This study directly addresses these identified priorities.

At root, ensuring good implementation of all TB IC procedures is a challenge of HCW behavior change. Even appropriate use of simple environmental control measures, requires a substantial element of behavior change to ensure effectiveness; for example, keeping needed windows open, ensuring needed fans are on and directed appropriately, and ensuring performance of routine maintenance checks of equipment. In this evaluation, the proposed intervention package focuses on tools and techniques that support the development of an institutional culture of safety and HCW behavior change regarding TB IC practices.

The theoretical framework for this intervention package is based on evidence showing that certain interventions favorably impact HCWs' IC practices and related patient outcomes, specifically 1) audits and feedback of IC performance and outcome data, 2) participation in IC collaborative (including mentoring), and 3) use of standardized IC checklists. Audit and feedback of performance have been used for decades as a strategy to improve implementation and adherence to clinical practice guidelines. Performance feedback has similarly been shown to be an effective intervention for improving IC practices. Also, there is a growing body of evidence to support the use of simple, evidence-based checklists as an effective IC strategy. When studied, use of checklists has fostered adoption of best practices, resulting in significant and sustained reductions in the targeted healthcare-associated infections (such as, surgical site infections and catheter-related bloodstream infections). Checklists are intended to be practical, easy-to-use tools that are designed to improve recall, prompt providers to perform recommended infection prevention steps, and make clear minimum expectations for IC. While the checklist approach has been used widely in other aspects of hospital IC, it has not yet been used widely for airborne IC. Lastly, collaboratives have been used to address a variety of health care issues and when studied in randomized trials, their efficacy has ranged from -16% to 70%. In Thailand, IC collaboratives have been associated with lower rates of healthcare-associated infections and better IC practices. In this study, we propose to use a robust study design to implement a multi-faceted TB IC package and to assess the impact of its implementation on TB transmission in hospitals and clinics where care is provided to patients with TB or other potential airborne respiratory infections.

Study Type

Observational

Enrollment (Actual)

22

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Cha Cherng Sao
      • Maruphong, Cha Cherng Sao, Thailand
        • Buddhasothorn Hospital
    • Chaiyaphum
      • Nai Mueang, Chaiyaphum, Thailand, 36000
        • Chaiyaphum Hosptial
    • Changwat Ratchaburi
      • Banpong, Changwat Ratchaburi, Thailand, 70110
        • Banpong Hospital
    • Chumpon
      • Mueang, Chumpon, Thailand
        • Chumponkhetudomsak Hospital
    • Nakhonnayok
      • Mueang Nakhonnayok, Nakhonnayok, Thailand, 26000
        • Nakhon Nayok Hospital
    • Nan
      • Nai Wiang, Mueang Nan, Nan, Thailand, 55000
        • Nan Hospital
    • Pichit
      • Nai Mueang, Pichit, Thailand, 66000
        • Pichit Hospital
    • Prachinburi
      • Mueang Prachinburi, Prachinburi, Thailand, 25000
        • Chao Phraya Abhaibhubejhr Hosptial
    • Praputtabat
      • Saraburi, Praputtabat, Thailand
        • Praputtabat Hosptial
    • Singburi
      • Mueang Singburi, Singburi, Thailand, 16000
        • Singburi Hospital
      • Binh Phuoc, Vietnam
        • Binh Phuoc General Hospital
      • Dong Nai, Vietnam
        • Dong Nai TB Hospital
      • Dong Thap, Vietnam
        • Dong Thap TB Hospial
      • Hai Duong, Vietnam
        • Hai Duong TB Hospital
      • Hoa Binh, Vietnam
        • Hoa Binh General Hospital
      • Hung Yen, Vietnam
        • Hung Yen Provincial Hospital
      • Long An, Vietnam
        • Long An General Hospital
      • Nam Dinh, Vietnam
        • Nam Dinh General Hospital
      • Quang Ninh, Vietnam
        • Quang Ninh TB Hospital
      • Tien Giang, Vietnam
        • Tien Giang General Hospital
      • Vinh Long, Vietnam
        • Vinh Long General Hosptial
      • Vinh Phuc, Vietnam
        • Vinh Phuc General Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

14 years to 41 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

This study will be conducted at 22 hospitals, 10 in Thailand and 12 in Vietnam. The study facilities will be hospitals that typically provide care to patients with confirmed or suspected TB, namely TB or general hospitals.

Description

Inclusion Criteria:

  • General provincial or regional hospital of at least 300 beds OR
  • TB or Respiratory hospitals of at least 100 beds
  • Geographic location that allows for ground transport of blood specimens to a designated reference laboratory within 16 hours of blood draw
  • Hospital director is willing to commit staff time to study participation, including designating personnel to oversee TB IC and EnTIC study activities, as evidenced by a letter of support for the study

Exclusion Criteria:

  • Specialty hospitals (such as, pediatric, infectious diseases, maternity)
  • Recent (within the past 3 years) or current participation in a TB IC initiative

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Other
  • Time Perspectives: Prospective

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Enhanced TB IC Package

Facilities randomized to the intervention group will receive the following:

  1. Skills-based training for TB IC focal points
  2. Audits and Feedback of performance data
  3. TB IC collaborative (including mentoring)
  4. Checklists

Facilities randomized to the intervention group will receive:

  1. Skills-based training addressing the hierarchy of TB IC measures, how to conduct a facility TB IC /risk assessment; and development, implementation, and monitoring of an operational TB IC plan for the facility
  2. Audits and Feedback of performance
  3. A TB IC collaborative membership
  4. A standardized unit-level daily checklist of critical IC activities
Usual Care Group
Usual Care group will receive available TB IC training/education alone.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in prevalence and incidence of latent Tuberculosis infection in healthcare workers
Time Frame: 0 months, 12 months, 24 months
Measured by an interferon gamma release assay, QuantiFERON-TB Gold In-Tube
0 months, 12 months, 24 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in institutional safety culture
Time Frame: 0 months and 24 months
Measured by the Hospital Survey on Patient Safety
0 months and 24 months
Adherence to recommended TB Infection Control practices
Time Frame: 0 months, 6 months, 12 months, 18 months, 24 months
Measured by observation of healthcare worker-patient encounters, turn-around-times, wait times, and time-to-treatment
0 months, 6 months, 12 months, 18 months, 24 months

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Cost data
Time Frame: 0 months, 6 months, 12 months, 18 months, 24 months
Measured by collecting costs associated with infection control
0 months, 6 months, 12 months, 18 months, 24 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Michele L Pearson, MD, Centers for Disease Control and Prevention, Center for Global Health, Division of Global HIV and TB
  • Principal Investigator: Sara J Whitehead, MD, Centers for Disease Control and Prevention

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

February 17, 2014

Primary Completion (Actual)

November 18, 2016

Study Completion (Actual)

November 18, 2016

Study Registration Dates

First Submitted

February 18, 2014

First Submitted That Met QC Criteria

February 25, 2014

First Posted (Estimate)

February 27, 2014

Study Record Updates

Last Update Posted (Actual)

February 2, 2021

Last Update Submitted That Met QC Criteria

February 1, 2021

Last Verified

December 1, 2020

More Information

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Tuberculosis

Clinical Trials on Enhanced TB IC Package

Subscribe